Back to Search
MATTHEW KULKE, MD
MD
Medical Oncology Physician
NPI: 1407823081Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
MD29756(ME)80794(MA)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
80794(MA)MD29756(ME)
Research & Publications (20)
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
PMID 19118063·Clin Cancer Res·2009
8-other
Neuroendocrine tumors: is there a standard treatment?
PMID 19259293·Gastrointest Cancer Res·2008
8-other
High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.
PMID 18383209·Genes Chromosomes Cancer·2008
8-other
New developments in the treatment of gastrointestinal neuroendocrine tumors.
PMID 17430688·Curr Oncol Rep·2007
6-review
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
PMID 17947726·J Clin Oncol·2007
8-other
Clinical presentation and management of carcinoid tumors.
PMID 17548033·Hematol Oncol Clin North Am·2007
6-review
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
PMID 17639038·Endocr Relat Cancer·2007
6-review
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
PMID 16865563·Dig Dis Sci·2006
3-trial
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
PMID 16877721·J Clin Oncol·2006
3-trial
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
PMID 16421420·J Clin Oncol·2006
3-trial
A phase II study of docetaxel in patients with metastatic carcinoid tumors.
PMID 15493355·Cancer Invest·2004
3-trial
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
PMID 15173710·J Thorac Cardiovasc Surg·2004
4-observational
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.
PMID 15329900·Cancer·2004
3-trial
Neuroendocrine tumours: clinical presentation and management of localized disease.
PMID 12972355·Cancer Treat Rev·2003
6-review
Advanced pancreatic cancer: is there a role for combination therapy?
PMID 14599095·Expert Rev Anticancer Ther·2003
6-review
Recent developments in the pharmacological treatment of advanced pancreatic cancer.
PMID 12783602·Expert Opin Investig Drugs·2003
6-review
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.
PMID 11259087·Br J Cancer·2001
8-other
p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
PMID 19302219·Dis Esophagus·2010
8-other
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
PMID 19620936·Pharmacogenet Genomics·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 830 HARRISON AVE, MOAKLEY ,3RD FOOR
BOSTON, MA 02118 - Phone
- (617) 638-6428
Quick Facts
- NPI
- 1407823081
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 3
- Publications
- 20
Are you this provider?
Claim Your Profile